Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16135-16150

  Leach, Damien A ^a   Need, Eleanor F ^a   Toivanen, Roxanne ^b   Trotta, Andrew P ^a   Palenthorpe, Helen M ^a   Tamblyn, David J ^c   Kopsaftis, Tina ^c   England, Georgina M ^d   Smith, Eric ^a   Drew, Paul A ^a,e   Pinnock, Carole B ^c   Lee, Peng ^f   Holst, Jeff ^g,h   Risbridger, Gail P ^b   Chopra, Samarth ^c,i,k   DeFranco, Donald B ^j   Taylor, Renea A ^b   Buchanan, Grant ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c REPATRIATION GENERAL HOSPITAL   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

^f NEW YORK UNIVERSITY   (United States)

^g CENTENARY INSTITUTE   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^k GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

more..

Author keywords

Androgen receptor; Extracellular matrix; Fibroblasts; Prostate cancer; Stroma

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN; AR PROTEIN, HUMAN; MESSENGER RNA;

AGED; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL CYCLE; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; MYOFIBROBLAST; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VERY ELDERLY; ANIMAL; APOPTOSIS; CANCER GRADING; CASE CONTROL STUDY; CELL MOTION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; DRUG EFFECTS; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; ORCHIECTOMY; PATHOLOGY; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TISSUE MICROARRAY; TUMOR CELL CULTURE; TUMOR INVASION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANDROGENS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MYOFIBROBLASTS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; ORCHIECTOMY; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STROMAL CELLS; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84937902220     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3873     Document Type: Article

References (63)

1. American Cancer Society I. (2012). Cancer Facts & Figures 2012. American Cancer Society).
2. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J and Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000; 164:101-105.
3. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC and Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294:433-439.
4. Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F and Fitzgerald RC. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A. 2010; 107:2177-2182.
5. Ma XJ, Dahiya S, Richardson E, Erlander M and Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009; 11:R7.
6. Brennen WN, Rosen DM, Wang H, Isaacs JT and Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation proteinactivated prodrug. J Natl Cancer Inst. 2012; 104:1320-1334.
7. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM and Woodson KG. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst. 2006; 98:255-261.
8. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ and Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev. 1987; 8:338-362.
9. Chung LW, Anderson NG, Neubauer BL, Cunha GR, Thompson TC and Rocco AK. Tissue interactions in prostate development: roles of sex steroids. Prog Clin Biol Res. 1981; 75A:177-203.
10. Thompson TC, Cunha GR, Shannon JM and Chung LW. Androgen-induced biochemical responses in epithelium lacking androgen receptors: characterization of androgen receptors in the mesenchymal derivative of urogenital sinus. J Steroid Biochem. 1986; 25:627-634.
11. Barron DA and Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer. 2012; 19:R187-204.
12. Clark AK, Taubenberger AV, Taylor RA, Niranjan B, Chea ZY, Zotenko E, Sieh S, Pedersen JS, Norden S, Frydenberg M, Grummet JP, Pook DW, Stirzaker C, Clark SJ, Lawrence MG, Ellem SJ, et al. A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials. 2013; 34:4777-4785.
13. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA and Kurita T. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol. 2004; 92:221-236.
14. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD and Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002; 8:2912-2923.
15. Schor SL, Schor AM and Rushton G. Fibroblasts from cancer patients display a mixture of both foetal and adultlike phenotypic characteristics. J Cell Sci. 1988; 90:401-407.
16. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD and Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59:5002-5011.
17. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS, Revelo MP, Bhowmick NA and Hayward SW. Altered TGF-beta signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res. 2011; 71:1272-1281.
18. Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L, Australian Prostate Cancer B, Collins AT, Maitland NJ and Risbridger GP. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Stem Cells. 2012; 30:1087-1096.
19. Bhowmick NA, Neilson EG and Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004; 432:332-337.
20. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG and Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004; 303:848-851.
21. Ao M, Franco OE, Park D, Raman D, Williams K and Hayward SW. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 2007; 67:4244-4253.
22. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR and Marker PC. Identification of SFRP1 as a candidate mediator of stromalto-epithelial signaling in prostate cancer. Cancer Res. 2005; 65:10423-10430.
23. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, Barczyk M, Panchal D, To C, Yun JJ, Der S, Shepherd FA, Jurisica I, et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2011; 108:7160-7165.
24. Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle JC and Stamenkovic I. Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS One. 2011; 6:e18640.
25. Wikstrom P, Marusic J, Stattin P and Bergh A. Low Stroma Androgen Receptor Level in Normal and Tumor Prostate Tissue Is Related to Poor Outcome in Prostate Cancer Patients. Prostate. 2009; 69:799-809.
26. Cunha GR, Chung LW, Shannon JM, Taguchi O and Fujii H. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Prog Horm Res. 1983; 39:559-598.
27. Scher HI, Buchanan G, Gerald W, Butler LM and Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004; 11:459-476.
28. Tindall DJ and Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008; 179:1235-1242.
29. Feldman BJ and Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer. 2001; 1:34-45.
30. Cunha GR and Donjacour A. Stromal-epithelial interactions in normal and abnormal prostatic development. Prog Clin Biol Res. 1987; 239:251-272.
31. Li Y, Li CX, Ye H, Chen F, Melamed J, Peng Y, Liu J, Wang Z, Tsou HC, Wei J, Walden P, Garabedian MJ and Lee P. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med. 2008; 12:2790-2798.
32. Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, Marshall VR, Horsfall DJ and Tilley WD. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate. 2005; 63:19-28.
33. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ and Sutherland RL. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001; 61:423-427.
34. Olapade-Olaopa EO, MacKay EH, Taub NA, Sandhu DP, Terry TR and Habib FK. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res. 1999; 5:569-576.
35. Lawrence MG, Taylor RA, Toivanen R, Pedersen J, Norden S, Pook DW, Frydenberg M, Papargiris MM, Niranjan B, Richards MG, Wang H, Collins AT, Maitland NJ and Risbridger GP. A preclinical xenograft model of prostate cancer using human tumors. Nat Protoc. 2013; 8:836-848.
36. Shang Y and Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 2002; 295:2465-2468.
37. Gregory CW, Johnson RT, Jr., Mohler JL, French FS and Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001; 61:2892-2898.
38. Santra MK, Wajapeyee N and Green MR. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature. 2009; 459:722-725.
39. Heitzer MD and DeFranco DB. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res. 2006; 66:7326-7333.
40. Matsuya M, Sasaki H, Aoto H, Mitaka T, Nagura K, Ohba T, Ishino M, Takahashi S, Suzuki R and Sasaki T. Cell adhesion kinase beta forms a complex with a new member, Hic-5, of proteins localized at focal adhesions. J Biol Chem. 1998; 273:1003-1014.
41. Leach DA, Need EF, Trotta AP, Grubisha MJ, Defranco DB and Buchanan G. Hic-5 influences genomic and nongenomic actions of the androgen receptor in prostate myofibroblasts. Mol Cell Endocrinol. 2014; 384:185-199.
42. Palumbo A, Jr., Ferreira LB, Reis de Souza PA, Oliveira FL, Pontes B, Viana NB, Machado DE, Palmero CY, Alves LM, Gimba ER and Nasciutti LE. Extracellular matrix secreted by reactive stroma is a main inducer of pro-tumorigenic features on LNCaP prostate cancer cells. Cancer Lett. 2012; 321:55-64.
43. Castello-Cros R and Cukierman E. Stromagenesis during tumorigenesis: characterization of tumor-associated fibroblasts and stroma-derived 3D matrices. Methods MolBiol. 2009; 522:275-305.
44. Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N and Staffurth J. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess. 2009; 13:iii, xi-xiii 1-219.
45. Ehrbar M, Sala A, Lienemann P, Ranga A, Mosiewicz K, Bittermann A, Rizzi SC, Weber FE and Lutolf MP. Elucidating the role of matrix stiffness in 3D cell migration and remodeling. Biophys J. 2011; 100:284-293.
46. Peyton SR and Putnam AJ. Extracellular matrix rigidity governs smooth muscle cell motility in a biphasic fashion. J Cell Physiol. 2005; 204:198-209.
47. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL and Weaver VM. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139:891-906.
48. Kauppila S, Bode MK, Stenback F, Risteli L and Risteli J. Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo. Br J Cancer. 1999; 81:654-661.
49. Kauppila S, Stenback F, Risteli J, Jukkola A and Risteli L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol. 1998; 186:262-268.
50. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S and Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A. 2008; 105:12182-12187.
51. Shigemura K, Isotani S, Wang R, Fujisawa M, Gotoh A, Marshall FF, Zhau HE and Chung LW. Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase. Prostate. 2009; 69:949-955.
52. Tanner MJ, Welliver RC, Jr., Chen M, Shtutman M, Godoy A, Smith G, Mian BM and Buttyan R. Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS One. 2011; 6:e16027.
53. Lai KP, Yamashita S, Huang CK, Yeh S and Chang C. Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines. EMBO Mol Med. 2012; 4:791-807.
54. Ricke EA, Williams K, Lee YF, Couto S, Wang Y, Hayward SW, Cunha GR and Ricke WA. Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Carcinogenesis. 2012;33:1391-1398.
55. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T, Trapman J, Romijn JC, van Weerden WM and Jenster G. Androgen receptor modifications in prostate cancer cells upon longtermandrogen ablation and antiandrogen treatment. Int J Cancer. 2005; 117:221-229.
56. Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH, Huang SP, Lardy H and Chang C. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci U S A. 2008; 105(34):12188-12193.
57. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S and Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994; 57:406-412.
58. Heitzer MD and DeFranco DB. Mechanism of action of Hic-5/androgen receptor activator 55, a LIM domaincontaining nuclear receptor coactivator. Mol Endocrinol. 2006; 20:56-64.
59. Need EF, Scher HI, Peters AA, Moore NL, Cheong A, Ryan CJ, Wittert GA, Marshall VR, Tilley WD and Buchanan G. A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology. 2009; 150:2674-2682.
60. Toivanen R, Berman DM, Wang H, Pedersen J, Frydenberg M, Meeker AK, Ellem SJ, Risbridger GP and Taylor RA. Brief report: a bioassay to identify primary human prostate cancer repopulating cells. Stem Cells. 2011; 29:1310-1314.
61. Trotta AP, Need EF, Butler LM, Selth LA, O'Loughlin MA, Coetzee GA, Tilley WD and Buchanan G. Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. J Mol Endocrinol. 2012; 49:57-68.
62. Humphries MJ. Cell adhesion assays. Methods Mol Biol. 2009; 522:203-210.
63. Ween MP, Hummitzsch K, Rodgers RJ, Oehler MK and Ricciardelli C. Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis. 2011; 28:113-125